サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1764306

機能不全性子宮出血の世界市場レポート 2025年

Dysfunctional Uterine Bleeding Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
機能不全性子宮出血の世界市場レポート 2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

機能不全性子宮出血市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で48億2,000万米ドルに成長します。予測期間に予測される成長は、月経障害の有病率の増加、女性の健康に対する意識の高まり、先進的診断技術の採用拡大、ヘルスケアインフラの拡大、低侵襲治療に対する需要の高まりによってもたらされます。この期間の主要動向には、非ホルモン治療オプションの進歩、月経障害の診断ツールの発展、低侵襲手術法の開発、月経健康追跡技術の革新、患者意識と教育イニシアチブの強化などがあります。

月経障害の有病率の上昇は、今後数年間の機能不全性子宮出血市場の成長を促進すると予想されます。月経障害には、出血の頻度、期間、量の変化など、月経周期の不規則性や異常が含まれます。月経異常の増加は、より多くの症例を特定し治療することを可能にする、より高い認識、ライフスタイルの変化、診断方法の改善によって促進されています。機能不全性子宮出血は、構造的あるいは全身的な疾患とは関連しない異常な子宮出血パターンを検出することで、月経障害の理解を助け、正確な診断と治療をサポートします。例えば、2023年12月、英国の非営利団体Trust for Londonは、英国では280万人が生理用品を購入するのに苦労しており、これは月経のある人の5人に1人に相当し、2022年の12％から2023年には21％へと大幅に増加していると報告しました。このように、月経障害の有病率の増加が機能不全性子宮出血市場の拡大に寄与しています。

機能不全性子宮出血市場の主要企業は、経口GnRH拮抗薬などの新しい治療法の開発に注力しており、ホルモンレベルを調整することで月経多量出血を軽減する効果的で非外科的な選択肢を提供しています。経口GnRH拮抗薬は、ゴナドトロピン放出ホルモン受容体をブロックし、エストロゲンレベルを下げ、侵襲的な処置を必要とせずに子宮筋腫を縮小させることで機能します。例えば、2024年9月、英国の製薬会社Theramexは、子宮筋腫に伴う月経多量出血の治療を目的とした1日1回投与の経口GnRH拮抗薬Yselty（リンザゴリックス）を発売しました。この治療は、個々の患者により適した治療ができるよう、柔軟な投与が可能です。患者のQOLを維持しながら症状を効果的に緩和し、治療中の妊孕性温存をサポートします。全体として、イセルティは子宮筋腫に関連する出血を管理するための革新的な戦略です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の機能不全性子宮出血：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の機能不全性子宮出血市場：成長率分析
  • 世界の機能不全性子宮出血市場の実績：規模と成長、2019～2024年
  • 世界の機能不全性子宮出血市場の予測：規模と成長、2024～2029年、2034年
  • 世界の機能不全性子宮出血：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の機能不全性子宮出血市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 排卵性
  • 無排卵性
  • 世界の機能不全性子宮出血市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
  • 子宮鏡検査
  • 超音波検査
  • 子宮内容除去術
  • 子宮内膜生検
  • 世界の機能不全性子宮出血市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
  • 閉経
  • 機能不全性子宮出血
  • 子宮内膜がん
  • 避妊
  • 過形成前駆病変
  • その他
  • 世界の機能不全性子宮出血市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • クリニック
  • 診断センター
  • 製薬会社
  • 世界の機能不全性子宮出血市場、排卵性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 月経過多
  • 頻月経
  • 不正出血
  • 月経困難症
  • 世界の機能不全性子宮出血市場、無排卵性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 無月経
  • 稀発月経
  • 機能不全出血
  • 突破出血

第7章 地域別・国別分析

  • 世界の機能不全性子宮出血市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の機能不全性子宮出血市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 機能不全性子宮出血市場：競合情勢
  • 機能不全性子宮出血市場：企業プロファイル
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Bayer AG
    • Sanofi S.A.

第31章 その他の大手企業と革新的企業

  • Medtronic plc
  • Boston Scientific Corporation
  • Smith & Nephew plc
  • Sun Pharmaceutical Industries Ltd.
  • Hologic Inc.
  • Sumitomo Pharma
  • Karl Storz SE & Co. KG
  • Cook Medical Incorporated
  • Gedeon Richter Plc
  • Lupin Ltd.
  • Torrent Pharmaceuticals Ltd.
  • CooperSurgical Inc.
  • Ferring Pharmaceuticals SA
  • Minerva Surgical Inc.
  • Medgyn Products Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 機能不全性子宮出血市場、2029年：新たな機会を提供する国
  • 機能不全性子宮出血市場、2029年：新たな機会を提供するセグメント
  • 機能不全性子宮出血市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35894

Dysfunctional uterine bleeding (DUB) is characterized by abnormal uterine bleeding, typically caused by hormonal imbalances rather than structural issues. It primarily affects women of reproductive age and can manifest as heavy, prolonged, or irregular menstrual periods. DUB is diagnosed when no pelvic pathology, systemic illness, or pregnancy-related cause is identified. Treatment varies based on the severity and the patient's reproductive intentions.

The main categories of dysfunctional uterine bleeding are ovulatory and anovulatory. Ovulatory DUB occurs despite regular ovulation and often includes conditions like menorrhagia, polymenorrhagia, metrorrhagia, and dysmenorrhea. Diagnostic methods include hysteroscopy, ultrasonography, dilation and curettage, and endometrial biopsy. These techniques are used in managing menopause, dysfunctional uterine bleeding, endometrial cancer, contraception, hyperplastic precursor lesions, and other conditions. The primary end users include hospitals, clinics, diagnostic centers, and pharmaceutical companies.

The dysfunctional uterine bleeding market research report is one of a series of new reports from The Business Research Company that provides dysfunctional uterine bleeding market statistics, including the dysfunctional uterine bleeding industry global market size, regional shares, competitors with the dysfunctional uterine bleeding market share, detailed dysfunctional uterine bleeding market segments, market trends, and opportunities, and any further data you may need to thrive in the dysfunctional uterine bleeding industry. This dysfunctional uterine bleeding market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dysfunctional uterine bleeding market size has grown strongly in recent years. It will grow from $3.29 billion in 2024 to $3.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be credited to the rising prevalence of hormonal imbalances, growing awareness of menstrual health, increased adoption of hormone therapy treatments, a higher number of women seeking gynecological care, and expanding research and development in women's health.

The dysfunctional uterine bleeding market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth projected for the forecast period is driven by the increasing prevalence of menstrual disorders, heightened awareness of women's health, greater adoption of advanced diagnostic techniques, expanding healthcare infrastructure, and a growing demand for minimally invasive treatments. Key trends during this period include progress in non-hormonal treatment options, improvements in diagnostic tools for menstrual disorders, development of minimally invasive surgical methods, innovations in menstrual health tracking technologies, and enhanced patient awareness and education initiatives.

The rising prevalence of menstrual disorders is expected to drive the growth of the dysfunctional uterine bleeding market in the coming years. Menstrual disorders encompass any irregularities or abnormalities in the menstrual cycle, such as changes in the frequency, duration, or volume of bleeding. This increase in menstrual disorders is fueled by greater awareness, lifestyle changes, and improved diagnostic methods that allow more cases to be identified and treated. Dysfunctional uterine bleeding aids in understanding menstrual disorders by detecting abnormal uterine bleeding patterns that are not linked to structural or systemic diseases, thereby supporting accurate diagnosis and treatment. For example, in December 2023, the Trust for London, a UK-based nonprofit, reported that 2.8 million people in the UK struggled to afford period products-equivalent to one in five menstruating individuals-and a significant rise from 12% in 2022 to 21% in 2023. Thus, the growing prevalence of menstrual disorders is contributing to the expansion of the dysfunctional uterine bleeding market.

Leading companies in the dysfunctional uterine bleeding market are concentrating on developing new treatments, such as oral GnRH antagonists, to offer effective, non-surgical options that reduce heavy menstrual bleeding by regulating hormone levels. An oral GnRH antagonist works by blocking gonadotropin-releasing hormone receptors, lowering estrogen levels, and shrinking uterine fibroids without the need for invasive procedures. For example, in September 2024, Theramex, a UK-based pharmaceutical firm, launched Yselty (linzagolix), an oral, once-daily GnRH antagonist aimed at treating heavy menstrual bleeding associated with uterine fibroids. This medication offers flexible dosing to better customize treatment for individual patients. It effectively alleviates symptoms while preserving patients' quality of life and supports fertility preservation during treatment. Overall, Yselty represents an innovative strategy for managing bleeding related to uterine fibroids.

In January 2025, Hologic Inc., a US-based medical technology company, acquired Gynesonics for $350 million. This acquisition adds the Sonata System to Hologic's portfolio-an innovative, incision-free treatment for uterine fibroids linked to heavy menstrual bleeding. The technology offers uterus-preserving options, strengthening Hologic's position in the abnormal uterine bleeding market. Gynesonics Inc., also based in the US, specializes in non-surgical medical devices that treat conditions causing dysfunctional uterine bleeding (DUB).

Major players in the dysfunctional uterine bleeding market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Medtronic plc, Boston Scientific Corporation, Smith & Nephew plc, Sun Pharmaceutical Industries Ltd., Hologic Inc., Sumitomo Pharma, Karl Storz SE & Co. KG, Cook Medical Incorporated, Gedeon Richter Plc, Lupin Ltd., Torrent Pharmaceuticals Ltd., CooperSurgical Inc., Ferring Pharmaceuticals SA, Minerva Surgical Inc., and Medgyn Products Inc.

North America was the largest region in the dysfunctional uterine bleeding market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysfunctional uterine bleeding report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dysfunctional uterine bleeding market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dysfunctional uterine bleeding market includes revenues earned by entities by providing services such as emergency care services, fertility and reproductive health services, and telemedicine and virtual care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dysfunctional Uterine Bleeding Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dysfunctional uterine bleeding market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dysfunctional uterine bleeding ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysfunctional uterine bleeding market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Ovulatory; Anovulatory
  • 2) By Diagnosis: Hysteroscopy; Ultrasonography; Dilation And Curettage; Endometrial Biopsy
  • 3) By Application: Menopause; Dysfunctional Uterine Bleeding; Endometrial Cancer; Contraception; Hyperplastic Precursor Lesions; Other Applications
  • 4) By End User: Hospital; Clinics; Diagnostic Centers; Pharmaceutical Companies
  • Subsegments:
  • 1) By Ovulatory: Menorrhagia; Polymenorrhea; Metrorrhagia; Dysmenorrhea
  • 2) By Anovulatory: Amenorrhea; Oligomenorrhea; Dysfunctional Bleeding; Breakthrough Bleeding
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dysfunctional Uterine Bleeding Market Characteristics

3. Dysfunctional Uterine Bleeding Market Trends And Strategies

4. Dysfunctional Uterine Bleeding Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Dysfunctional Uterine Bleeding Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Dysfunctional Uterine Bleeding PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Dysfunctional Uterine Bleeding Market Growth Rate Analysis
  • 5.4. Global Dysfunctional Uterine Bleeding Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Dysfunctional Uterine Bleeding Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Dysfunctional Uterine Bleeding Total Addressable Market (TAM)

6. Dysfunctional Uterine Bleeding Market Segmentation

  • 6.1. Global Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ovulatory
  • Anovulastory
  • 6.2. Global Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hysteroscopy
  • Ultrasonography
  • Dilation And Curettage
  • Endometrial Biopsy
  • 6.3. Global Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Menopause
  • Dysfunctional Uterine Bleeding
  • Endometrial Cancer
  • Contraception
  • Hyperplastic Precursor Lesions
  • Other Applications
  • 6.4. Global Dysfunctional Uterine Bleeding Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Clinics
  • Diagnostic Centers
  • Pharmaceutical Companies
  • 6.5. Global Dysfunctional Uterine Bleeding Market, Sub-Segmentation Of Ovulatory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Menorrhagia
  • Polymenorrhea
  • Metrorrhagia
  • Dysmenorrhea
  • 6.6. Global Dysfunctional Uterine Bleeding Market, Sub-Segmentation Of Anovulatory, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Amenorrhea
  • Oligomenorrhea
  • Dysfunctional Bleeding
  • Breakthrough Bleeding

7. Dysfunctional Uterine Bleeding Market Regional And Country Analysis

  • 7.1. Global Dysfunctional Uterine Bleeding Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Dysfunctional Uterine Bleeding Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dysfunctional Uterine Bleeding Market

  • 8.1. Asia-Pacific Dysfunctional Uterine Bleeding Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dysfunctional Uterine Bleeding Market

  • 9.1. China Dysfunctional Uterine Bleeding Market Overview
  • 9.2. China Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dysfunctional Uterine Bleeding Market

  • 10.1. India Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dysfunctional Uterine Bleeding Market

  • 11.1. Japan Dysfunctional Uterine Bleeding Market Overview
  • 11.2. Japan Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dysfunctional Uterine Bleeding Market

  • 12.1. Australia Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dysfunctional Uterine Bleeding Market

  • 13.1. Indonesia Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dysfunctional Uterine Bleeding Market

  • 14.1. South Korea Dysfunctional Uterine Bleeding Market Overview
  • 14.2. South Korea Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dysfunctional Uterine Bleeding Market

  • 15.1. Western Europe Dysfunctional Uterine Bleeding Market Overview
  • 15.2. Western Europe Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dysfunctional Uterine Bleeding Market

  • 16.1. UK Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dysfunctional Uterine Bleeding Market

  • 17.1. Germany Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dysfunctional Uterine Bleeding Market

  • 18.1. France Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dysfunctional Uterine Bleeding Market

  • 19.1. Italy Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dysfunctional Uterine Bleeding Market

  • 20.1. Spain Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dysfunctional Uterine Bleeding Market

  • 21.1. Eastern Europe Dysfunctional Uterine Bleeding Market Overview
  • 21.2. Eastern Europe Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dysfunctional Uterine Bleeding Market

  • 22.1. Russia Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dysfunctional Uterine Bleeding Market

  • 23.1. North America Dysfunctional Uterine Bleeding Market Overview
  • 23.2. North America Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dysfunctional Uterine Bleeding Market

  • 24.1. USA Dysfunctional Uterine Bleeding Market Overview
  • 24.2. USA Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dysfunctional Uterine Bleeding Market

  • 25.1. Canada Dysfunctional Uterine Bleeding Market Overview
  • 25.2. Canada Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dysfunctional Uterine Bleeding Market

  • 26.1. South America Dysfunctional Uterine Bleeding Market Overview
  • 26.2. South America Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dysfunctional Uterine Bleeding Market

  • 27.1. Brazil Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dysfunctional Uterine Bleeding Market

  • 28.1. Middle East Dysfunctional Uterine Bleeding Market Overview
  • 28.2. Middle East Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dysfunctional Uterine Bleeding Market

  • 29.1. Africa Dysfunctional Uterine Bleeding Market Overview
  • 29.2. Africa Dysfunctional Uterine Bleeding Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Dysfunctional Uterine Bleeding Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Dysfunctional Uterine Bleeding Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dysfunctional Uterine Bleeding Market Competitive Landscape And Company Profiles

  • 30.1. Dysfunctional Uterine Bleeding Market Competitive Landscape
  • 30.2. Dysfunctional Uterine Bleeding Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Dysfunctional Uterine Bleeding Market Other Major And Innovative Companies

  • 31.1. Medtronic plc
  • 31.2. Boston Scientific Corporation
  • 31.3. Smith & Nephew plc
  • 31.4. Sun Pharmaceutical Industries Ltd.
  • 31.5. Hologic Inc.
  • 31.6. Sumitomo Pharma
  • 31.7. Karl Storz SE & Co. KG
  • 31.8. Cook Medical Incorporated
  • 31.9. Gedeon Richter Plc
  • 31.10. Lupin Ltd.
  • 31.11. Torrent Pharmaceuticals Ltd.
  • 31.12. CooperSurgical Inc.
  • 31.13. Ferring Pharmaceuticals SA
  • 31.14. Minerva Surgical Inc.
  • 31.15. Medgyn Products Inc.

32. Global Dysfunctional Uterine Bleeding Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dysfunctional Uterine Bleeding Market

34. Recent Developments In The Dysfunctional Uterine Bleeding Market

35. Dysfunctional Uterine Bleeding Market High Potential Countries, Segments and Strategies

  • 35.1 Dysfunctional Uterine Bleeding Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Dysfunctional Uterine Bleeding Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Dysfunctional Uterine Bleeding Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer